

Chapter 57

REFERENCES

1. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. *Am J Gastroenterol*. 2001;96(5):1581-1586.
2. Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease. *Clin Liver Dis*. 2009;13(1):21-31.
3. Gresele P, Binetti BM, Branca G, et al. TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival. *Thromb Res*. 2008;121(6):763-768.
4. Hersch SL, Kunelis T, Francis RB Jr. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. *Blood*. 1987;69(5):1315-1319.
5. Knot EA, Drijfhout HR, ten Cate JW, et al. α_2 -Plasmin inhibitor metabolism in patients with liver cirrhosis. *J Lab Clin Med*. 1985;105(3):353-358.
6. Leebeek FW, Klufft C, Knot EA, De Maat MP. Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis. *J Lab Clin Med*. 1989;113(4):493-497.
7. Leebeek FW, Klufft C, Knot EA, de Maat MP, Wilson JH. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. *Gastroenterology*. 1991;101(5):1382-1390.
8. Steib A, Gengenwin N, Freys G, Boudjema K, Levy S, Otteni JC. Predictive factors of hyperfibrinolytic activity during liver transplantation in cirrhotic patients. *Br J Anaesth*. 1994;73(5):645-648.
9. Russell DW. Fifty years of advances in bile acid synthesis and metabolism. *J Lipid Res*. 2009;50(Suppl):S120-S125.
10. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. *Annu Rev Biochem*. 2003;72:137-174.
11. Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. *Hepatology*. 2009;50(3):825-833.
12. Babington JR, Stahl JH, Coy DL. Reversible cytotoxic edema in a cirrhotic patient following TIPS. *J Neuroimag*. 2009;19(4):391-393.
13. Somberg KA, Riegler JL, LaBerge JM, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. *Am J Gastroenterol*. 1995;90(4):549-555.
14. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. *Ann Intern Med*. 2002;137(12):947-954.
15. Gazzard BG, Portmann B, Murray-Lyon IM, Williams R. Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. *Q J Med*. 1975;44(176):615-626.
16. Blei AT, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. *Lancet*. 1993;341(8838):157-158.
17. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. *Liver Transpl*. 2005;11(12):1581-1589.
18. Le TV, Rumbak MJ, Liu SS, Alsina AE, Van Loveren H, Agazzi S. Insertion of intracranial pressure monitors in fulminant hepatic failure patients. *Neurosurgery*. 2010;66(3):455-458.
19. Dmello D, Cruz-Flores S, Matuschak GM. Moderate hypothermia with intracranial pressure monitoring as a therapeutic paradigm for the management of acute liver failure: a systematic review. *Intensive Care Med*. 2010;36(2):210-213.
20. Vaquero J, Rose C, Butterworth RF. Keeping cool in acute liver failure: rationale for the use of mild hypothermia. *J Hepatol*. 2005;43(6):1067-1077.
21. Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. *Semin Liver Dis*. 1996;16(4):389-402.
22. Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. *Hepatology*. 1995;21(5):1328-1336.
23. Trevisani F, Sica G, Mainqua P, et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. *Hepatology*. 1999;30(6):1387-1392.
24. Henriksen JH, Moller S, Schifter S, Bendtsen F. Increased arterial compliance in decompensated cirrhosis. *J Hepatol*. 1999;31(4):712-718.
25. Moller S, Bendtsen F, Schifter S, Henriksen JH. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis. *Scand J Gastroenterol*. 1996;31(9):928-933.
26. Lee FY, Lin HC, Tsai YT, et al. Plasma substance P levels in patients with liver cirrhosis: relationship to systemic and portal hemodynamics. *Am J Gastroenterol*. 1997;92(11):2080-2084.
27. Henriksen JH, Moller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. *J Hepatol*. 1998;29(2):328-341.

28. Fernandez-Rodriguez CM, Prieto J, Zozaya JM, Quiroga J, Guitian R. Arteriovenous shunting, hemodynamic changes, and renal sodium retention in liver cirrhosis. *Gastroenterology*. 1993;104(4):1139-1145.
29. Jha SK, Kumar A, Sharma BC, Sarin SK. Systemic and pulmonary hemodynamics in patients with extrahepatic portal vein obstruction is similar to compensated cirrhotic patients. *Hepatology Int*. 2009;3(2):384-391.
30. Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. *J Am Coll Cardiol*. 2010;56(7):539-549.
31. Møller S, Henriksen JH. Cirrhotic cardiomyopathy. *J Hepatol*. 2010;53(1):179-190.
32. Caraceni P, Giannone F, Bernardi M. The role of the endocannabinoid system in liver diseases. *Best Pract Res Clin Endocrinol Metab*. 2009;23(1):65-77.
33. Sampathkumar P, Lerman A, Kim BY, et al. Post-liver transplantation myocardial dysfunction. *Liver Transpl Surg*. 1998;4(5):399-403.
34. Pham PT, Pham PC, Rastogi A, Wilkinson AH. Review article: current management of renal dysfunction in the cirrhotic patient. *Aliment Pharmacol Ther*. 2005;21(8):949-961.
35. Terra C, Guevara M, Torre A, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. *Gastroenterology*. 2005;129(6):1944-1953.
36. Cardenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. *Am J Gastroenterol*. 2005;100(2):460-467.
37. Lim Y-S, Larson TS, Benson JT, et al. Serum sodium, renal function, and survival of patients with end-stage liver disease. *J Hepatol*. 2010;52(4):523-528.
38. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. *Hepatology*. 1988;8(5):1151-1157.
39. Kayali Z, Herring J, Baron P, et al. Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction. *J Gastroenterol Hepatol*. 2009;24(6):1030-1037.
40. Lieberman FL. Functional renal failure in cirrhosis. *Gastroenterology*. 1970;58(1):108-110.
41. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. *J Gastroenterol Hepatol*. 2010;25(2):880-885.
42. Xu X, Ling Q, Zhang M, et al. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. *Transplantation*. 2009;87(10):1514-1519.
43. Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. *Gut*. 2010;59(1):105-110.
44. Pham DM, Subramanian R, Parekh S. Coexisting hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. *J Clin Gastroenterol*. 2010;44(7):e136-e140.
45. Hoepfer MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. *Lancet*. 2004;363(9419):1461-1468.
46. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. *Gut*. 2003;52(9):1355-1362.
47. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. *Circulation*. 1989;80(5):1198-1206.
48. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. *J Am Coll Cardiol*. 1991;17(2):492-498.
49. Robalino BD, Moodie DS. Primary pulmonary hypertension, then and now: 28 years of experience. *Cleve Clin J Med*. 1992;59(4):411-417.
50. Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. *Transplantation*. 2001;71(4):572-574.
51. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. *Hepatology*. 2003;37(2):401-409.
52. Bandara M, Gordon FD, Sarwar A, et al. Successful outcomes following living donor liver transplantation for portopulmonary hypertension. *Liver Transpl*. 2010;16(8):983-989.
53. Kuo PC, Plotkin JS, Gaine S, et al. Portopulmonary hypertension and the liver transplant candidate. *Transplantation*. 1999;67(8):1087-1093.
54. Krowka MJ, Frantz RP, McGoan MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. *Hepatology*. 1999;30(3):641-648.
55. Findlay JY, Harrison BA, Plevak DJ, Krowka MJ. Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. *Liver Transpl Surg*. 1999;5(5):381-387.
56. Mair P, Kaehler CH, Pomaroli A, Schwarz B, Vogel W, Margreiter R. Orthotopic liver transplantation in a patient with severe portopulmonary hypertension. *Acta Anaesthesiol Scand*. 2001;45(4):513-518.
57. Findlay JY, Plevak DJ, Krowka MJ, Sack EM, Porayko MK. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. *Liver Transpl Surg*. 1999;5(5):362-365.
58. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. *Liver Transpl*. 2004;10(2):174-182.
59. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med*. 2002;165(6):800-804.
60. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. *J Am Coll Cardiol*. 2002;39(9):1496-1502.
61. Hoepfer MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. *N Engl J Med*. 2000;342(25):1866-1870.
62. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med*. 2002;347(5):322-329.

63. Schroeder RA, Wood GL, Plotkin JS, Kuo PC. Intraoperative use of inhaled PGI(2) for acute pulmonary hypertension and right ventricular failure. *Anesth Analg.* 2000;91(2):291-295.
64. Melgosa MT, Ricci GL, Garc a-Pagan JC, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. *Liver Transpl.* 2010;16:348-356.
65. Krowka MJ. Hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. *Clin Chest Med.* 2005;26(4):587-597, vi.
66. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. *Lancet.* 1991;338(8776):1173-1174.
67. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. *Circulation.* 2002;105(20):2398-2403.
68. Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. *J Heart Lung Transplant.* 2005;24(4):498-500.
69. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. *Liver Transpl.* 2004;10(7):945-950.
70. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. *J Am Coll Cardiol.* 2003;42(1):158-164.
71. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. *Eur Respir J.* 2005;25(3):502-508.
72. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. *Eur Respir J.* 2007;30(6):1096-1102.
73. Jiang BH, Tardif J-C, Shi Y, Dupuis J. Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. *Eur Respir J.* 2011;37(3):578-586.
74. Palma DT, Fallon MB. The hepatopulmonary syndrome. *J Hepatol.* 2006;45(4):617-625.
75. Abrams GA, Nanda NC, Dubovsky EV, Krowka MJ, Fallon MB. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. *Gastroenterology.* 1998;114(2):305-310.
76. Martinez G, Barbera JA, Navasa M, Roca J, Visa J, Rodriguez-Roisin R. Hepatopulmonary syndrome associated with cardiorespiratory disease. *J Hepatol.* 1999;30(5):882-889.
77. Stoller JK. As the liver goes, so goes the lung. *Chest.* 1990;97(5):1028-1030.
78. Rolla G, Brussino L, Colagrande P, et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. *Hepatology.* 1997;26(4):842-847.
79. Cremona G, Higenbottam TW, Mayoral V, et al. Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. *Eur Respir J.* 1995;8(11):1883-1885.
80. Arguedas MR, Singh H, Faulk DK, Fallon MB. Utility of pulse oximetry screening for hepatopulmonary syndrome. *Clin Gastroenterol Hepatol.* 2007;5(6):749-754.
81. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. *Hepatology.* 2000;32(4 Pt 1):859-865.
82. Battaglia SE, Pretto JJ, Irving LB, Jones RM, Angus PW. Resolution of gas exchange abnormalities and intrapulmonary shunting following liver transplantation. *Hepatology.* 1997;25(5):1228-1232.
83. Collisson EA, Nourmand H, Fraiman MH, et al. Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. *Liver Transpl.* 2002;8(10):925-931.
84. Kim HY, Choi MS, Lee SC, et al. Outcomes in patients with hepatopulmonary syndrome undergoing liver transplantation. *Transplant Proc.* 2004;36(9):2762-2763.
85. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. *Hepatology.* 2005;41(5):1122-1129.
86. Schenk P, Schoniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Muller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. *Gastroenterology.* 2003;125(4):1042-1052.
87. Aboussouan LS, Stoller JK. The hepatopulmonary syndrome. *Baillieres Best Pract Res Clin Gastroenterol.* 2000;14(6):1033-1048.
88. Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. *Hepatology.* 2003;37(1):192-197.
89. Sigal SH, Stanca CM, Kontorinis N, Bodian C, Ryan E. Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. *Am J Gastroenterol.* 2006;101(7):1490-1496.
90. Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. *Hepatology.* 1998;28(2):374-378.
91. Als-Nielsen B, Gluud LL, Gluud C. Benzodiazepine receptor antagonists for hepatic encephalopathy. *Cochrane Database Syst Rev.* 2004(2):CD002798.
92. Takahashi K, Kameda H, Kataoka M, Sanjou K, Harata N, Akaike N. Ammonia potentiates GABA_A response in dissociated rat cortical neurons. *Neurosci Lett.* 1993;151(1):51-54.
93. Cauli O, Mansouri MT, Agusti A, Felipo V. Hyperammonemia increases GABAergic tone in the cerebellum but decreases it in the rat cortex. *Gastroenterology.* 2009;136(4):1359-1367, e1351-e1352.
94. Chaudhry V, Corse AM, O'Brian R, Cornblath DR, Klein AS, Thuluvath PJ. Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: a clinical and electrophysiologic study. *Hepatology.* 1999;29(6):1698-1703.
95. McDougall AJ, Davies L, McCaughan GW. Autonomic and peripheral neuropathy in endstage liver disease and following liver transplantation. *Muscle Nerve.* 2003;28(5):595-600.
96. Verne GN, Soldevia-Pico C, Robinson ME, Spicer KM, Reuben A. Autonomic dysfunction and gastroparesis in cirrhosis. *J Clin Gastroenterol.* 2004;38(1):72-76.
97. Latson TW, Ashmore TH, Reinhart DJ, Klein KW, Giesecke AH. Autonomic reflex dysfunction in patients presenting for elective surgery is associated with hypotension after anesthesia induction. *Anesthesiology.* 1994;80(2):326-337.
98. Fleckenstein JF, Frank S, Thuluvath PJ. Presence of autonomic neuropathy is a poor prognostic indicator in patients with advanced liver disease. *Hepatology.* 1996;23(3):471-475.
99. Perez-Pena J, Rincon D, Banares R, et al. Autonomic neuropathy in end-stage cirrhotic patients and evolution after liver transplantation. *Transplant Proc.* 2003;35(5):1834-1835.
100. Foster JH, Berman MM. Solid liver tumors. *Major Probl Clin Surg.* 1977;22:1-342.

101. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. *Ann Surg.* 2002;236(4):397-406; discussion 406-397.
102. Allen PJ, Jarnagin WR. Current status of hepatic resection. *Adv Surg.* 2003;37:29-49.
103. Pol B, Campan P, Hardwigsen J, Botti G, Pons J, Le Treut YP. Morbidity of major hepatic resections: a 100-case prospective study. *Eur J Surg.* 1999;165(5):446-453.
104. Melendez JA, Arslan V, Fischer ME, et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. *J Am Coll Surg.* 1998;187(6):620-625.
105. Poon RT. Recent advances in techniques of liver resection. *Surg Technol Int.* 2004;13:71-77.
106. Brand MI, Saclarides TJ, Dobson HD, Millikan KW. Liver resection for colorectal cancer: liver metastases in the aged. *Am Surg.* 2000;66(4):412-415; discussion 415-416.
107. Fong Y, Brennan MF, Cohen AM, Heffernan N, Freiman A, Blumgart LH. Liver resection in the elderly. *Br J Surg.* 1997;84(10):1386-1390.
108. Cescon M, Grazi GL, Del Gaudio M, et al. Outcome of right hepatectomies in patients older than 70 years. *Arch Surg.* 2003;138(5):547-552.
109. Emond JC, Samstein B, Renz JF. A critical evaluation of hepatic resection in cirrhosis: optimizing patient selection and outcomes. *World J Surg.* 2005;29(2):124-130.
110. Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. *Ann Surg.* 2003;237(6):860-869; discussion 869-870.
111. Abdalla EK, Noun R, Belghiti J. Hepatic vascular occlusion: which technique? *Surg Clin North Am.* 2004;84(2):563-585.
112. Emond JC, Kelley SD, Heffron TG, Nakagawa T, Roberts JP, Lim RC Jr. Surgical and anesthetic management of patients undergoing major hepatectomy using total vascular exclusion. *Liver Transpl Surg.* 1996;2(2):91-98.
113. Cherqui D, Malassagne B, Colau PI, Brunetti F, Rotman N, Fagniez PL. Hepatic vascular exclusion with preservation of the caval flow for liver resections. *Ann Surg.* 1999;230(1):24-30.
114. Si-Yuan FU, Yee LW, Guang-Gang L, et al. A prospective randomized controlled trial to compare Pringle maneuver, hemihepatic vascular inflow occlusion, and main portal vein inflow occlusion in partial hepatectomy. *Am J Surg.* 2011;201(1):62-69.
115. Lentschener C, Ozier Y. Anaesthesia for elective liver resection: some points should be revisited. *Eur J Anaesthesiol.* 2002;19(11):780-788.
116. Redai I, Emond J, Brentjens T. Anesthetic considerations during liver surgery. *Surg Clin North Am.* 2004;84(2):401-411.
117. Niemann CU, Roberts JP, Ascher NL, Yost CS. Intraoperative hemodynamics and liver function in adult-to-adult living liver donors. *Liver Transpl.* 2002;8(12):1126-1132.
118. Thasler WE, Bein T, Jauch KW. Perioperative effects of hepatic resection surgery on hemodynamics, pulmonary fluid balance, and indocyanine green clearance. *Langenbecks Arch Surg.* 2002;387(7-8):271-275.
119. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Anesth Analg.* 2008;106(3):685-712.
120. Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. *N Engl J Med.* 1996;334(19):1209-1215.
121. Spahn DR, Rossaint R. Coagulopathy and blood component transfusion in trauma. *Br J Anaesth.* 2005;95(2):130-139.
122. Nishiyama T, Fujimoto T, Hanaoka K. A comparison of liver function after hepatectomy in cirrhotic patients between sevoflurane and isoflurane in anesthesia with nitrous oxide and epidural block. *Anesth Analg.* 2004;98(4):990-993, table of contents.
123. Ko JS, Gwak MS, Choi SJ, et al. The effects of desflurane and sevoflurane on hepatic and renal functions after right hepatectomy in living donors. *Transpl Int.* 2010;23(3):736-744.
124. Brooks AJ, Eastwood J, Beckingham IJ, Girling KJ. Liver tissue partial pressure of oxygen and carbon dioxide during partial hepatectomy. *Br J Anaesth.* 2004;92(5):735-737.
125. Lentschener C, Franco D, Bouaziz H, et al. Haemodynamic changes associated with portal triad clamping are suppressed by prior hepatic pedicle infiltration with lidocaine in humans. *Br J Anaesth.* 1999;82(5):691-697.
126. Jones RM, Moulton CE, Hardy KJ. Central venous pressure and its effect on blood loss during liver resection. *Br J Surg.* 1998;85(8):1058-1060.
127. Smyrniotis V, Kostopanagiotou G, Theodoraki K, Tsantoulas D, Contis JC. The role of central venous pressure and type of vascular control in blood loss during major liver resections. *Am J Surg.* 2004;187(3):398-402.
128. Dixon E, Vollmer CM Jr, Bathe OF, Sutherland F. Vascular occlusion to decrease blood loss during hepatic resection. *Am J Surg.* 2005;190(1):75-86.
129. Taurà P, Fuster J, Mercadal J, et al. The use of β -adrenergic drugs improves hepatic oxygen metabolism in cirrhotic patients undergoing liver resection. *J Hepatol.* 2010;52(3):340-347.
130. Wong AY, Irwin MG, Hui TW, Fung SK, Fan ST, Ma ES. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. *Can J Anaesth.* 2003;50(1):14-20.
131. Lentschener C, Benhamou D, Mercier FJ, et al. Aprotinin reduces blood loss in patients undergoing elective liver resection. *Anesth Analg.* 1997;84(4):875-881.
132. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. *N Engl J Med.* 2006;354(4):353-365.
133. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. *Anesthesiology.* 2005;102(2):269-275.
134. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. *JAMA.* 2006;295(3):293-298.
135. Siniscalchi A, Begliomini B, Matteo G, De Pietri L, Pasetto A. Intraoperative effects of combined versus general anesthesia during major liver surgery. *Minerva Anestesiol.* 2003;69(12):885-895.
136. Page A, Rostad B, Staley CA, et al. Epidural analgesia in hepatic resection. *J Am Coll Surg.* 2008;206(3):1184-1192.

137. Choi SJ, Gwak MS, Ko JS, et al. The changes in coagulation profile and epidural catheter safety for living liver donors: a report on 6 years of our experience. *Liver Transpl.* 2007;13(1):62-70.
138. Adornato DC, Gildenberg PL, Ferrario CM, Smart J, Frost EA. Pathophysiology of intravenous air embolism in dogs. *Anesthesiology.* 1978;49(2):120-127.
139. Koo BN, Kil HK, Choi JS, Kim JY, Chun DH, Hong YW. Hepatic resection by the Cavitron Ultrasonic Surgical Aspirator increases the incidence and severity of venous air embolism. *Anesth Analg.* 2005;101(4):966-970, table of contents.
140. Ousmane ML, Fleyfel M, Vallet B. Venous gas embolism during liver surgery with argon-enhanced coagulation. *Eur J Anaesthesiol.* 2002;19(3):225.
141. Lee SY, Choi BI, Kim JS, Park KS. Paradoxical air embolism during hepatic resection. *Br J Anaesth.* 2002;88(1):136-138.
142. Baer HU, Blumgart LH. Venous air embolism with a water jet dissector. *Br J Anaesth.* 1993;71:921.
143. Diakun TA. Carbon dioxide embolism: successful resuscitation with cardiopulmonary bypass. *Anesthesiology.* 1991;74(6):1151-1153.
144. Seu P, Neelankanta G, Csete M, et al. Liver transplantation for fulminant hepatic failure in a Jehovah's Witness. *Clin Transplant.* 1996;10(5):404-407.
145. Snook NJ, O'Beirne HA, Enright S, Young Y, Bellamy MC. Use of recombinant human erythropoietin to facilitate liver transplantation in a Jehovah's Witness. *Br J Anaesth.* 1996;76(5):740-743.
146. Jabbour N, Gagandeep S, Mateo R, Sher L, Genyk Y, Selby R. Transfusion-free surgery: single institution experience of 27 consecutive liver transplants in Jehovah's Witnesses. *J Am Coll Surg.* 2005;210(3):412-417.
147. Jeffrey GP, McCall J, Gane E, et al. Liver transplantation in Jehovah's Witness patients in Australasia. *Med J Aust.* 2007;187(3):188-189.
148. Hillingso JG, Wettergren A, Hyoudo M, Kirkegaard P. Obesity increases mortality in liver transplantation—the Danish experience. *Transpl Int.* 2005;18(11):1231-1235.
149. Fallon MB, Mulligan DC, Gish RG, Krowka MJ. Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. *Liver Transpl.* 2006;12(12 Suppl 3):S105-S107.
150. Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac morbidity and mortality related to orthotopic liver transplantation. *Liver Transpl.* 2004;10(12):1441-1453.
151. Carey WD, Dumot JA, Pimentel RR, et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. *Transplantation.* 1995;59(6):859-864.
152. Morris JJ, Hellman CL, Gawey BJ, et al. Case 3-1995. Three patients requiring both coronary artery bypass surgery and orthotopic liver transplantation. *J Cardiothorac Vasc Anesth.* 1995;9(3):322-332.
153. Keefe BG, Valentine H, Keefe EB. Detection and treatment of coronary artery disease in liver transplant candidates. *Liver Transpl.* 2001;7(9):755-761.
154. Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. *Liver Transpl Surg.* 1996;2(6):426-430.
155. Plevak DJ. Stress echocardiography identifies coronary artery disease in liver transplant candidates. *Liver Transpl Surg.* 1998;4(4):337-339.
156. Plotkin JS, Benitez RM, Kuo PC, et al. Dobutamine stress echocardiography for preoperative cardiac risk stratification in patients undergoing orthotopic liver transplantation. *Liver Transpl Surg.* 1998;4(4):253-257.
157. Plotkin JS, Johnson LB, Rustgi V, Kuo PC. Coronary artery disease and liver transplantation: the state of the art. *Liver Transpl.* 2000;6(4 Suppl 1):S53-S56.
158. Beattie WS, Abdelnaem E, Wijesundera DN, Buckley DN. A meta-analytic comparison of preoperative stress echocardiography and nuclear scintigraphy imaging. *Anesth Analg.* 2006;102(1):8-16.
159. Donovan CL, Marcovitz PA, Punch JD, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. *Transplantation.* 1996;61(8):1180-1188.
160. Williams K, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. *Transplantation.* 2000;69(11):2354-2356.
161. Harinstein ME, Flaherty JD, Ansari AH, et al. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. *Am J Transplant.* 2008;8(7):1523-1528.
162. Maraj S, Jacobs LE, Maraj R, et al. Inducible left ventricular outflow tract gradient during dobutamine stress echocardiography: an association with intraoperative hypotension but not a contraindication to liver transplantation. *Echocardiography.* 2004;21(8):681-685.
163. Bizouarn P, Ausseur A, Desseigne P, et al. Early and late outcome after elective cardiac surgery in patients with cirrhosis. *Ann Thorac Surg.* 1999;67(5):1334-1338.
164. Klemperer JD, Ko W, Krieger KH, et al. Cardiac operations in patients with cirrhosis. *Ann Thorac Surg.* 1998;65(1):85-87.
165. Axelrod D, Koffron A, Dewolf A, et al. Safety and efficacy of combined orthotopic liver transplantation and coronary artery bypass grafting. *Liver Transpl.* 2004;10(11):1386-1390.
166. Eckhoff DE, Frenette L, Sellers MT, et al. Combined cardiac surgery and liver transplantation. *Liver Transpl.* 2001;7(1):60-61.
167. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. *Liver Transpl.* 2000;6(4 Suppl 1):S44-S52.
168. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. *Gut.* 2008;57(2):268-278.
169. Lerner AB, Sundar E, Mahmood F, Sarge T, Hanto DW, Panzica PJ. Four cases of cardiopulmonary thromboembolism during liver transplantation without the use of antifibrinolytic drugs. *Anesth Analg.* 2005;101(6):1608-1612.
170. Gologorsky E, De Wolf AM, Scott V, Aggarwal S, Dishart M, Kang Y. Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. *Liver Transpl.* 2001;7(9):783-789.
171. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. *Mayo Clin Proc.* 1984;59(1):17-20.
172. Alba AC, Verocai Flaman F, Granton J, Delgado DH. Patent foramen ovale does not have a negative impact on early outcomes in patients undergoing liver transplantation. *Clin Transplant.* 2011;25(1):151-155.
173. Bijl JM, Ruygrok PN, Hornung TS, Wilson NJ, West T. Percutaneous closure of patent foramen ovale. *Intern Med J.* 2005;35(12):706-710.

174. Ellis JE, Lichtor JL, Feinstein SB, et al. Right heart dysfunction, pulmonary embolism, and paradoxical embolization during liver transplantation. A transesophageal two-dimensional echocardiographic study. *Anesth Analg*. 1989;68(6):777-782.
175. Mohrs OK, Petersen SE, Erkapic D, et al. Diagnosis of patent foramen ovale using contrast-enhanced dynamic MRI: a pilot study. *AJR Am J Roentgenol*. 2005;184(1):234-240.
176. Pilatis ND, Jacobs LE, Rerkpattanapipat P, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. *Liver Transpl*. 2000;6(1):85-91.
177. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. *Liver Transpl*. 2000;6(4):443-450.
178. Starkel P, Vera A, Gunson B, Mutimer D. Outcome of liver transplantation for patients with pulmonary hypertension. *Liver Transpl*. 2002;8(4):382-388.
179. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. *Am J Transplant*. 2008;8(11):2445-2453.
180. Reddy K, Mallett S, Peachey T. Venovenous bypass in orthotopic liver transplantation: time for a rethink? *Liver Transpl*. 2005;11(7):741-749.
181. Schwarz B, Pomaroli A, Hoermann C, Margreiter R, Mair P. Liver transplantation without venovenous bypass: morbidity and mortality in patients with greater than 50% reduction in cardiac output after vena cava clamping. *J Cardiothorac Vasc Anesth*. 2001;15(4):460-462.
182. Wall WJ, Grant DR, Duff JH, Kutt JL, Ghent CN, Bloch MS. Liver transplantation without venous bypass. *Transplantation*. 1987;43(1):56-61.
183. Grande L, Rimola A, Cugat E, et al. Effect of venovenous bypass on perioperative renal function in liver transplantation: results of a randomized, controlled trial. *Hepatology*. 1996;23(6):1418-1428.
184. Shaw BW Jr, Martin DJ, Marquez JM, et al. Venous bypass in clinical liver transplantation. *Ann Surg*. 1984;200(4):524-534.
185. Tisone G, Mercadante E, Dauri M, et al. Surgical versus percutaneous technique for veno-venous bypass during orthotopic liver transplantation: a prospective randomized study. *Transplant Proc*. 1999;31(8):3162-3163.
186. Washburn WK, Lewis WD, Jenkins RL. Percutaneous venovenous bypass in orthotopic liver transplantation. *Liver Transpl Surg*. 1995;1(6):377-382.
187. Budd JM, Isaac JL, Bennett J, Freeman JW. Morbidity and mortality associated with large-bore percutaneous venovenous bypass cannulation for 312 orthotopic liver transplantations. *Liver Transpl*. 2001;7(4):359-362.
188. Griffith BP, Shaw BW Jr, Hardesty RL, Iwatsuki S, Bahnson HT, Starzl TE. Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. *Surg Gynecol Obstet*. 1985;160(3):270-272.
189. Calne RY, Williams R. Liver transplantation in man. I. Observations on technique and organization in five cases. *Br Med J*. 1968;4(630):535-540.
190. Lerut J, Ciccarelli O, Roggen F, et al. Cavocaval adult liver transplantation and retransplantation without venovenous bypass and without portocaval shunting: a prospective feasibility study in adult liver transplantation. *Transplantation*. 2003;75(10):1740-1745.
191. Cabezuelo JB, Ramirez P, Acosta F, et al. Does the standard vs piggyback surgical technique affect the development of early acute renal failure after orthotopic liver transplantation? *Transplant Proc*. 2003;35(5):1913-1914.
192. Walsh TS, Hopton P, Garden OJ, Lee A. Effect of graft reperfusion on haemodynamics and gas exchange during liver transplantation. *Br J Anaesth*. 1998;81(3):311-316.
193. Sakai T, Matsusaki T, Marsh JW, Hilmi IA, Planinsic RM. Comparison of surgical methods in liver transplantation: retrohepatic caval resection with venovenous bypass (VVB) versus piggyback (PB) with VVB versus PB without VVB. *Transpl Int*. 2010;23(12):1247-1258.
194. Mehrabi A, Mood ZA, Fonouni H, et al. A single-center experience of 500 liver transplants using the modified piggyback technique by Belghiti. *Liver Transpl*. 2009;15:466-474.
195. Moreno-Gonzalez E, Meneu-Diaz JG, Fundora Y, et al. Advantages of the piggy back technique on intraoperative transfusion, fluid compsumption, and vasoactive drugs requirements in liver transplantation: a comparative study. *Transplant Proc*. 2003;35(5):1918-1919.
196. Figueras J, Llado L, Ramos E, et al. Temporary portocaval shunt during liver transplantation with vena cava preservation. Results of a prospective randomized study. *Liver Transpl*. 2001;7(10):904-911.
197. Schumann R. Intraoperative resource utilization in anesthesia for liver transplantation in the United States: a survey. *Anesth Analg*. 2003;97(1):21-28, table of contents.
198. Arnal D, Garutti I, Perez-Pena J, Olmedilla L, Tzenkov IG. Radial to femoral arterial blood pressure differences during liver transplantation. *Anaesthesia*. 2005;60(8):766-771.
199. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. *Clin Infect Dis*. 2004;38(12):1706-1715.
200. Wu Y, Oyos TL, Chenhsu RY, Katz DA, Brian JE, Rayhill SC. Vasopressor agents without volume expansion as a safe alternative to venovenous bypass during cavaplasty liver transplantation. *Transplantation*. 2003;76(12):1724-1728.
201. Schroeder RA, Collins BH, Tuttle-Newhall E, et al. Intraoperative fluid management during orthotopic liver transplantation. *J Cardiothorac Vasc Anesth*. 2004;18(4):438-441.
202. Feng Z-Y, Xu X, Zhu S-M, Bein B, Zheng S-S. Effects of low central venous pressure during preanhepatic phase on blood loss and renal function in liver transplantation. *World J Surg*. 2010;34(8):1864-1873.
203. Xia VW, Du B, Braunfeld M, et al. Preoperative characteristics and intraoperative transfusion and vasopressor requirements in patients with low vs. high MELD scores. *Liver Transpl*. 2006;12(4):614-620.
204. Mehrabi A, Golling M, Kashfi A, et al. Negative impact of systemic catecholamine administration on hepatic blood perfusion after porcine liver transplantation. *Liver Transpl*. 2005;11(2):174-187.
205. Dubois MJ, De Backer D, Creteur J, Anane S, Vincent JL. Effect of vasopressin on sublingual microcirculation in a patient with distributive shock. *Intensive Care Med*. 2003;29(6):1020-1023.
206. Luckner G, Dunser MW, Jochberger S, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. *Crit Care Med*. 2005;33(11):2659-2666.
207. Wagener G, Gubitosa G, Renz J, et al. Vasopressin decreases portal vein pressure and flow in the native liver during liver transplantation. *Liver Transpl*. 2008;14(11):1664-1670.

208. Narahara Y, Kanazawa H, Taki Y, et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. *J Gastroenterol Hepatol.* 2009;24(11):1791-1797.
209. Findlay JY, Kufner RP. Aprotinin reduces vasoactive medication use during adult liver transplantation. *J Clin Anesth.* 2003; 15(1):19-23.
210. Hammer GB, Krane EJ. Anaesthesia for liver transplantation in children. *Paediatr Anaesth.* 2001;11(1):3-18.
211. Kang YG, Martin DJ, Marquez J, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. *Anesth Analg.* 1985;64(9):888-896.
212. Salooja N, Perry DJ. Thrombelastography. *Blood Coagul Fibrinolysis.* 2001;12(5):327-337.
213. Kang Y. Coagulation and liver transplantation: current concepts. *Liver Transpl Surg.* 1997;3(4):465-467.
214. Krenn CG, Hoda R, Nikolic A, et al. Assessment of ventricular contractile function during orthotopic liver transplantation. *Transpl Int.* 2004;17(2):101-104.
215. Gouvêa G, Diaz R, Auler L, Martinho JM. Evaluation of the right ventricular ejection fraction during orthotopic liver transplantation under propofol anaesthesia. *Br J Anaesth.* 2008; 101(2):161-165.
216. Drummond JC, Petrovitch CT. The massively bleeding patient. *Anesthesiol Clin North Am.* 2001;19(4):633-649.
217. Li Q, Zhou MT, Wang Y, et al. Effect of insulin on hyperkalemia during anhepatic stage of liver transplantation. *World J Gastroenterol.* 2004;10(16):2427-2429.
218. Kim D-K, Chang S-H, Yun I-J, Kwon W-K, Woo N-S. Salbutamol to facilitate management of acute hyperkalemia in liver transplantation: a case report. *Can J Anaesth.* 2009; 56(2):142-146.
219. Marquez J, Martin D, Virji MA, et al. Cardiovascular depression secondary to ionic hypocalcemia during hepatic transplantation in humans. *Anesthesiology.* 1986;65(5):457-461.
220. Gainza FJ, Valdivieso A, Quintanilla N, et al. Evaluation of acute renal failure in the liver transplantation perioperative period: incidence and impact. *Transplant Proc.* 2002;34(1): 250-251.
221. Lima EQ, Zanetta DM, Castro I, et al. Risk factors for development of acute renal failure after liver transplantation. *Ren Fail.* 2003;25(4):553-560.
222. Lafayette RA, Pare G, Schmid CH, King AJ, Rohrer RJ, Nasraway SA. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. *Clin Nephrol.* 1997;48(3): 159-164.
223. Biancofiore G, Della Rocca G, Bindi L, et al. Use of fenoldopam to control renal dysfunction early after liver transplantation. *Liver Transpl.* 2004;10(8):986-992.
224. Della Rocca G, Pompei L, Costa MG, et al. Fenoldopam mesylate and renal function in patients undergoing liver transplantation: a randomized, controlled pilot trial. *Anesth Analg.* 2004;99(6):1604-1609, table of contents.
225. Pugliese F, Ruberto F, Bruno K, et al. Fenoldopam and gastric tonometry during orthotopic liver transplantation. *Transplant Proc.* 2007;39(6):1886-1888.
226. De Wolf AM, Begliomini B, Gasior TA, Kang Y, Pinsky MR. Right ventricular function during orthotopic liver transplantation. *Anesth Analg.* 1993;76(3):562-568.
227. Saada M, Liu N, Cherqui D, et al. [Opening of a foramen ovale during liver transplantation. The value of transesophageal echocardiography]. *Ann Fr Anesth Reanim.* 1990;9(5):412-414.
228. Schwarz B, Mair P, Margreiter J, et al. Experience with percutaneous venoarterial cardiopulmonary bypass for emergency circulatory support. *Crit Care Med.* 2003;31(3):758-764.
229. Kang Y, Lewis JH, Navalgund A, et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. *Anesthesiology.* 1987;66(6):766-773.
230. Cheema SP, Webster NR, Dunn F, Bellamy MC. Mediators of fibrinolysis in orthotopic liver transplantation. *Clin Transplant.* 1996;10(1 Pt 1):24-27.
231. Porte RJ, Bontempo FA, Knot EA, Lewis JH, Kang YG, Starzl TE. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. *Transplantation.* 1989;47(6): 978-984.
232. Segal H, Cottam S, Potter D, Hunt BJ. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. *Hepatology.* 1997;25(3):683-688.
233. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. *Lancet.* 2000;355(9212):1303-1309.
234. Xia VW, Steadman RH. Antifibrinolytics in orthotopic liver transplantation: current status and controversies. *Liver Transpl.* 2005;11(1):10-18.
235. Fitzsimons MG, Peterfreund RA, Raines DE. Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: report of two cases. *Anesth Analg.* 2001;92(6):1418-1421.
236. Lentschener C, Roche K, Ozier Y. A review of aprotinin in orthotopic liver transplantation: can its harmful effects offset its beneficial effects? *Anesth Analg.* 2005;100(5): 1248-1255.
237. Kalicinski P, Markiewicz M, Kaminski A, et al. Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation. *Pediatr Transplant.* 2005;9(3):299-304.
238. Meijer K, Hendriks HG, De Wolf JT, et al. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. *Blood Coagul Fibrinolysis.* 2003;14(2):169-174.
239. Roth E, Steininger R, Winkler S, et al. L-Arginine deficiency after liver transplantation as an effect of arginase efflux from the graft. Influence on nitric oxide metabolism. *Transplantation.* 1994;57(5):665-669.
240. Längle F, Steininger R, Roth R, et al. L-arginine deficiency and hemodynamic changes as a result of arginase efflux following orthotopic liver transplantation. *Transplant Proc.* 1995;27(5):2872-2873.
241. Becker T, Mevius I, de Vries DK, et al. The L-arginine/NO pathway in end-stage liver disease and during orthotopic liver and kidney transplantation: biological and analytical ramifications. *Nitric Oxide.* 2009;20(1):61-67.
242. Yagnik GP, Takahashi Y, Tsoulfas G, Reid K, Murase N, Geller DA. Blockade of the L-arginine/NO synthase pathway worsens hepatic apoptosis and liver transplant preservation injury. *Hepatology.* 2002;36(3):573-581.
243. Längle F, Steininger R, Waldmann E, et al. Improvement of cardiac output and liver blood flow and reduction of pulmonary vascular resistance by intravenous infusion of L-arginine during the early reperfusion period in pig liver transplantation. *Transplantation.* 1997;63(9):1225-1233.

244. Jeyabalan G, Klune JR, Nakao A, et al. Arginase blockade protects against hepatic damage in warm ischemia-reperfusion. *Nitric Oxide*. 2008;19(1):29-35.
245. Mandell MS, Stoner TJ, Barnett R, et al. A multicenter evaluation of safety of early extubation in liver transplant recipients. *Liver Transpl*. 2007;13(11):1557-1563.
246. Biancofiore G, Romanelli AM, Bindi ML, et al. Very early tracheal extubation without predetermined criteria in a liver transplant recipient population. *Liver Transpl*. 2001;7(9):777-782.
247. Ponnudurai RN, Koneru B, Akhtar SA, et al. Vasopressor administration during liver transplant surgery and its effect on endotracheal reintubation rate in the postoperative period: a prospective, randomized, double-blind, placebo-controlled trial. *Clin Ther*. 2005;27(2):192-198.
248. Biancofiore G, Bindi ML, Romanelli AM, et al. Postoperative intra-abdominal pressure and renal function after liver transplantation. *Arch Surg*. 2003;138(7):703-706.
249. Krenn CG, Krafft P, Schaefer B, et al. Effects of positive end-expiratory pressure on hemodynamics and indocyanine green kinetics in patients after orthotopic liver transplantation. *Crit Care Med*. 2000;28(6):1760-1765.
250. Trzebicki J, Nicinska B, Blaszczyk B, et al. Thoracic epidural analgesia in anaesthesia for liver transplantation: the 10-year experience of a single centre. *Ann Transplant*. 2010;15(2):35-39.
251. Moretti EW, Robertson KM, Tuttle-Newhall JE, Clavien PA, Gan TJ. Orthotopic liver transplant patients require less postoperative morphine than do patients undergoing hepatic resection. *J Clin Anesth*. 2002;14(6):416-420.
252. Romundstad L, Breivik H, Roald H, et al. Methylprednisolone reduces pain, emesis, and fatigue after breast augmentation surgery: a single-dose, randomized, parallel-group study with methylprednisolone 125 mg, parecoxib 40 mg, and placebo. *Anesth Analg*. 2006;102(2):418-425.
253. Toy P, Gajic O. Transfusion-related acute lung injury. *Anesth Analg*. 2004;99(6):1623-1624, table of contents.
254. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. *Crit Care Med*. 2005;33(4):721-726.
255. Yost CS, Matthay MA, Gropper MA. Etiology of acute pulmonary edema during liver transplantation: a series of cases with analysis of the edema fluid. *Chest*. 2001;119(1):219-223.
256. Pereboom ITA, de Boer MT, Haagsma EB, Hendriks HGD, Lisman T, Porte RJ. Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury. *Anesth Analg*. 2009;108(4):1083-1091.
257. Sykes E, Cosgrove JF, Nesbitt ID, O'Suilleabhain CB. Early noncardiogenic pulmonary edema and the use of PEEP and prone ventilation after emergency liver transplantation. *Liver Transpl*. 2007;13(3):459-462.
258. Ljungman P. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. *Br J Haematol*. 2004;125(2):107-116.
259. Razonable RR. Cytomegalovirus infection after liver transplantation. *Liver Transpl*. 2010;16(S2):S45-S53.
260. Crossin JD, Muradali D, Wilson SR. US of liver transplants: normal and abnormal. *Radiographics*. 2003;23(5):1093-1114.
261. Singh AK, Nachiappan AC, Verma HA, et al. Postoperative imaging in liver transplantation: what radiologists should know. *Radiographics*. 2010;30(2):339-351.
262. Singhal A, Stokes K, Sebastian A, Wright HI, Kohli V. Endovascular treatment of hepatic artery thrombosis following liver transplantation. *Transpl Int*. 2010;23(3):245-256.
263. Dubost T, Goubaux B, Duhalde M, Raucoules-Aime M, Wolkiewicz J, Gugenheim J. Use of hyperbaric oxygen for hepatic artery thrombosis following adult orthotopic liver transplantation. *Eur J Anaesthesiol*. 2002;19(3):223-224.
264. Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. *Ann Intern Med*. 1997;126(1):57-62.
265. Bronster DJ, Emre S, Boccagni P, Sheiner PA, Schwartz ME, Miller CM. Central nervous system complications in liver transplant recipients—incidence, timing, and long-term follow-up. *Clin Transplant*. 2000;14(1):1-7.
266. Bonham CA, Dominguez EA, Fukui MB, et al. Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. *Transplantation*. 1998;66(12):1596-1604.
267. Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. *Gastroenterology*. 2007;133(3):825-834.
268. Saab S, Nieto JM, Lewis SK, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. *Cochrane Database Syst Rev*. 2006:CD004889.
269. Merli M, Valeriano V, Funaro S, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). *Am J Gastroenterol*. 2002;97(1):142-148.
270. Rumi MN, Schumann R, Freeman RB, Rohrer RJ, Fairchild RB. Acute transjugular intrahepatic portosystemic shunt migration into pulmonary artery during liver transplantation. *Transplantation*. 1999;67(11):1492-1494.
271. McCowan TC, Hummel MM, Schmucker T, Goertzen TC, Culp WC, Habbe TG. Cardiac perforation and tamponade during transjugular intrahepatic portosystemic shunt placement. *Cardiovasc Intervent Radiol*. 2000;23(4):298-300.
272. Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. *J Hepatol*. 2005;42(5):674-679.
273. Nygaard CE, Townsend RN, Diamond DL. Organ donor management and organ outcome: a 6-year review from a Level I trauma center. *J Trauma*. 1990;30(6):728-732.
274. Razek T, Olthoff K, Reilly PM. Issues in potential organ donor management. *Surg Clin North Am*. 2000;80(3):1021-1032.
275. Szabo G. Physiologic changes after brain death. *J Heart Lung Transplant*. 2004;23(9 Suppl):S223-S226.
276. Avlonitis VS, Fisher AJ, Kirby JA, Dark JH. Pulmonary transplantation: the role of brain death in donor lung injury. *Transplantation*. 2003;75(12):1928-1933.
277. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. *Am J Transplant*. 2006;6(4):783-790.
278. Feng S. The dilemma of high-risk deceased donor livers: who should get them? *Liver Transpl*. 2010;16(S2):S60-S64.
279. Grewal HP, Thistlewaite JR Jr, Loss GE, et al. Complications in 100 living-liver donors. *Ann Surg*. 1998;228(2):214-219.
280. Lutz JT, Valentin-Gamazo C, Goring K, Malago M, Peters J. Blood-transfusion requirements and blood salvage in donors undergoing right hepatectomy for living related liver transplantation. *Anesth Analg*. 2003;96(2):351-355, table of contents.

281. Tanabe M, Kawachi S, Obara H, et al. Current progress in ABO-incompatible liver transplantation. *Eur J Clin Invest.* 2010;40(10):943-949.
282. Sahani D, Mehta A, Blake M, Prasad S, Harris G, Saini S. Preoperative hepatic vascular evaluation with CT and MR angiography: implications for surgery. *Radiographics.* 2004;24(5):1367-1380.
283. Boermeester MA, Straatsburg IH, Houdijk AP, et al. Endotoxin and interleukin-1 related hepatic inflammatory response promotes liver failure after partial hepatectomy. *Hepatology.* 1995;22(5):1499-1506.
284. Ayanoglu HO, Ulukaya S, Yuzer Y, Tokat Y. Anesthetic management and complications in living donor hepatectomy. *Transplant Proc.* 2003;35(8):2970-2973.
285. Beebe DS, Carr R, Komanduri V, Humar A, Gruessner R, Belani KG. Living liver donor surgery: report of initial anesthesia experience. *J Clin Anesth.* 2000;12(2):157-161.
286. Matot I, Scheinin O, Eid A, Jurim O. Epidural anesthesia and analgesia in liver resection. *Anesth Analg.* 2002;95(5):1179-1181, table of contents.
287. Siniscalchi A, Begliomini B, De Pietri L, et al. Increased prothrombin time and platelet counts in living donor right hepatectomy: implications for epidural anesthesia. *Liver Transpl.* 2004;10(9):1144-1149.
288. Cywinski JB, Parker BM, Xu M, Irefin SA. A comparison of postoperative pain control in patients after right lobe donor hepatectomy and major hepatic resection for tumor. *Anesth Analg.* 2004;99(6):1747-1752, table of contents.
289. Schumann R, Zabala L, Angelis M, Bonney I, Tighiouart H, Carr DB. Altered hematologic profiles following donor right hepatectomy and implications for perioperative analgesic management. *Liver Transpl.* 2004;10(3):363-368.
290. Cerutti E, Stratta C, Romagnoli R, et al. Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation. *Liver Transpl.* 2004;10(2):289-294.
291. Ozkardesler S, Ozzeybek D, Alaygut E, et al. Anesthesia-related complications in living liver donors: the experience from one center and the reporting of one death. *Am J Transplant.* 2008;8(10):2106-2110.
292. Chhibber A, Dziak J, Kolano J, Norton JR, Lustik S. Anesthesia care for adult live donor hepatectomy: our experiences with 100 cases. *Liver Transpl.* 2007;13(4):537-542.
293. Garcia-Valdecasas JC, Tabet J, Valero R, et al. Evaluation of ischemic injury during liver procurement from non-heart-beating donors. *Eur Surg Res.* 1999;31(6):447-456.
294. Foley DP, Fernandez LA, Levenson G, et al. Donation after cardiac death: the University of Wisconsin experience with liver transplantation. *Ann Surg.* 2005;242(5):724-731.